TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2010

Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.

Elaine M Sloand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.